content: <HTML><HEAD>
  <TITLE>Prepared by R.R. Donnelley Financial -- Form 8-K</TITLE>
  </HEAD>
    <BODY BGCOLOR="WHITE">
   <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="5" COLOR="#000000"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></DIV> <DIV ALIGN="center"><FONT
  FACE="Times New Roman" SIZE="3" COLOR="#000000"><B>WASHINGTON, D.C. 20549 </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <HR NOSHADE WIDTH="21%" COLOR="#000000"><DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT
  FACE="Times New Roman" SIZE="5" COLOR="#000000"><B>FORM 8-K </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>Current Report </B></FONT></DIV> <DIV
  ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>Pursuant to Section 13 or 15(d) of The </B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>Securities Exchange Act of 1934
  </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>Date of Report (Date of earliest event reported): May 23, 2002 </B></FONT></DIV> <DIV><FONT
  SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="5" COLOR="#000000"><B>CONCEPTUS, INC. </B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>(Exact name of registrant as
  specified in charter) </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center">
  <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">
  
  <TR>
  <TD VALIGN="top" ALIGN="center" WIDTH="31%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>Delaware</B></FONT></DIV> <HR NOSHADE WIDTH="96%" COLOR="#000000" ALIGN="left"><DIV ALIGN="center"><FONT FACE="Times New Roman"
  SIZE="1" COLOR="#000000"><B>(State or other jurisdiction of</B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>incorporation or organization)</B></FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="top" ALIGN="center" WIDTH="31%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>000-27596</B></FONT></DIV> <HR NOSHADE WIDTH="93%" COLOR="#000000" ALIGN="left"><DIV ALIGN="center"><FONT
  FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>(Commission file number)</B></FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="top" ALIGN="center" WIDTH="31%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>97-3170244</B></FONT></DIV> <HR NOSHADE WIDTH="96%" COLOR="#000000" ALIGN="left"><DIV ALIGN="center"><FONT
  FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>(I.R.S. employer</B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>identification no.)</B></FONT></DIV> </TD> </TR>
   </TABLE> </DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>1021 Howard Avenue </B></FONT></DIV> <DIV ALIGN="center"><FONT
  FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>San Carlos, CA 94070 </B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>(Address of principal executive offices) (Zip code) </B></FONT></DIV> <DIV><FONT
  SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>Registrant&#146;s telephone number, including area code:&nbsp;&nbsp;&nbsp;&nbsp;(650) 802-7240 </B></FONT></DIV> <DIV><FONT
  SIZE="1">&nbsp;</FONT></DIV> <HR NOSHADE WIDTH="21%" COLOR="#000000">
  
  <p Style='page-break-before:always'>
  <HR  SIZE="3" COLOR="#CCEEFF" WIDTH="100%" ALIGN="CENTER">
   <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>ITEM 5.&nbsp;&nbsp;&nbsp;&nbsp;OTHER EVENTS. </B></FONT></DIV> <DIV><FONT
  SIZE="1">&nbsp;</FONT></DIV> <DIV STYLE="text-indent:4%"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">On May 23, 2002, Conceptus, Inc. issued a press release announcing that the Company&#146;s Premarket Approval (PMA) application for
  <I>Essure </I>has been accepted by U.S. Food and Drug Administration (FDA) as suitable for filing, and that the application will be reviewed during the July meeting of the FDA&#146;s Obstetrics and Gynecology Devices Panel. Text of the press release
  follows: </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">SAN CARLOS, Calif. (May 23, 2002) &#150; Conceptus, Inc. (NASDAQ NM: CPTS), developer
  of the non-incisional permanent birth control procedure <I>Essure</I><I></I></FONT><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><I><SUP>&#153;</SUP></I></FONT><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><I><SUP></SUP></I>, has
  been advised by the U.S. Food and Drug Administration (FDA) that the Company&#146;s Premarket Approval (PMA) application for <I>Essure </I>has been accepted as suitable for filing, or deemed &#147;fileable,&#148; and that the application will be
  reviewed during the July 22-23 meeting of the FDA&#146;s Obstetrics and Gynecology Devices Panel. In addition, the PMA application has been granted Expedited Review status. Based on the FDA Modernization Act of 1997, Expedited Review is granted for
  devices intended to provide a &#147;more effective treatment or diagnosis of life-threatening or irreversibly debilitating human diseases or conditions.&#148; Accordingly, Expedited Review is to be granted &#147;for devices: 1) representing
  breakthrough technologies; 2) for which no approved alternatives exist; 3) which offer significant advantages over existing approved alternatives; or, 4) the availability of which is in the best interest of patients.&#148; </FONT></DIV> <DIV><FONT
  SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">&#147;We are grateful that the Agency has acted so swiftly in regards to our <I>Essure</I> PMA submission,&#148; commented Steven Bacich, chief executive
  officer. &#147;In granting Expedited Review status, the FDA stated that they &#145;believe <I>Essure </I>may offer a significant advantage in female sterilization,&#146; because, &#145;This device is delivered by a hysteroscopic procedure, without
  the need for an abdominal incision. In addition, in the majority of women, the placement procedure does not require general anesthesia.&#146;&#148; </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2"
  COLOR="#000000">In commenting on U.S. commercialization, Steve Bowman, senior vice president of sales and marketing, said, &#147;We intend to immediately commence certain aspects of our commercialization plan for Essure in the U.S., and to be ready
  to market shortly after receiving approval. In anticipation of potential FDA approval which, given the Expedited Review and the July Panel meeting, could come as early as the end of this year, we plan to accelerate our preparatory activities for
  U.S. commercialization so that we may bring this innovative method of permanent birth control to the women of the United States in the most expeditious manner possible.&#148; </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT
  FACE="Times New Roman" SIZE="2" COLOR="#000000">Cindy Domecus, senior vice president of clinical research and regulatory affairs, said, &#147;According to the FDA&#146;s guidelines on Expedited Review, our application should receive priority review
  before other pending applications. Furthermore, the guidelines state that our application should be reviewed in the most efficient manner, be tracked as an Expedited Review, and be completed within the statutory time frames.&#148; </FONT></DIV>
  <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">The first module of the <I>Essure </I>PMA was filed last November, and the final PMA application was submitted to the FDA on April 19, 2002. The PMA
  submission included one-year data on 360 women with bilateral placement in the Pivotal trial. When combined with data from the Phase II trial, the PMA contained data on almost 900 women-years of reliance on the device. By the time of the panel
  review, data on 400 women with bilateral placement and one-year follow-up will have been submitted. To date, there have been no reported pregnancies in woman relying on Essure in either the Phase II or Pivotal trials, which supports a projected
  one-year effectiveness rate of 99.8%. The Company cautions that no method of birth control is 100% effective and that pregnancies are expected to occur. </FONT></DIV> <P></P>
   <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">2 </FONT></DIV>
  
  
  <p Style='page-break-before:always'>
  <HR  SIZE="3" COLOR="#CCEEFF" WIDTH="100%" ALIGN="CENTER">
   <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>PERMANENT BIRTH CONTROL </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT
  FACE="Times New Roman" SIZE="2" COLOR="#000000">According to the United States Centers for Disease Control and Prevention, surgical tubal ligation continues to be the most prevalent form of birth control in the U.S., with 41 percent of women using
  contraceptives age 35-39 and 50 percent of women using contraceptives age 40-44 having had a surgical tubal sterilization. An estimated 700,000 surgical tubal ligations are performed each year in the United States, despite the fact that it is
  invasive and costly. About 93 percent of the laparoscopic procedures in the U.S. are performed in a hospital or surgi-center under general anesthesia, requiring between four and five hours of hospital recovery time and four to six days before
  returning to regular activities. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Development of a non-incisional method of tubal ligation has been an elusive goal for researchers since
  the 1970&#146;s. <I>Essure</I> is currently an investigational device for non-incisional permanent birth control. <B></B> </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>ABOUT
  CONCEPTUS </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Conceptus, Inc. is developing <I>Essure</I>, an innovative medical procedure, designed to provide a non-incisional
  alternative to tubal ligation, the leading form of birth control worldwide. The availability of <I>Essure </I>in the U.S. is projected for 2003 and is expected to open up a market currently occupied by surgical tubal ligation and vasectomy, which
  combined account for more than 1 million procedures in the United States. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">The <I>Essure </I>procedure is based on a unique and
  proprietary implant and catheter delivery system for minimally invasive transcervical tubal access. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><I>Except for the historical
  information contained herein, the matters discussed in this press release are forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. The receipt and timing of regulatory approvals, results of product
  development programs, and clinical efficacy of and market demand for our product, among other matters discussed in this release, may differ significantly from the discussion of such matters in the forward-looking statements. Such differences may be
  based upon factors such as strategic planning decisions by management, re-allocation of internal resources, performance of independent distributors, delays by regulatory authorities, scientific advances by third parties, introduction of competitive
  products, as well as those factors set forth in the Company&#146;s Annual Report on Form 10-K for the year ended December 31, 2001 and other filings with the Securities and Exchange Commission. </I></FONT></DIV> <DIV><FONT
  SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"
  COLOR="#000000">#&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;#&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;# </FONT></DIV> <P></P>
   <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">3 </FONT></DIV>
  
  
  <p Style='page-break-before:always'>
  <HR  SIZE="3" COLOR="#CCEEFF" WIDTH="100%" ALIGN="CENTER">
   <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>SIGNATURES </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV
  STYLE="text-indent:4%"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
  authorized. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="right">
  <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">
  
  <TR>
  <TD VALIGN="top" COLSPAN="3" WIDTH="43%"> <DIV STYLE="margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">CONCEPTUS, INC.</FONT></DIV> <DIV STYLE="margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman"
  SIZE="2" COLOR="#000000">(Registrant)</FONT></DIV> </TD> </TR>
  <TR>
  <TD HEIGHT="16"> </TD> </TR>
  <TR>
  <TD VALIGN="top" WIDTH="3%"> <DIV STYLE="margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">By:</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="top" WIDTH="43%"> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">/s/&nbsp;&nbsp;&nbsp;&nbsp;Glen K. Furuta</FONT></DIV> <HR NOSHADE COLOR="#000000" ALIGN="left"></TD> </TR>
  <TR>
  <TD> <FONT SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="bottom" WIDTH="43%"> <DIV STYLE="margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Glen K. Furuta</FONT></DIV> <DIV STYLE="margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2"
  COLOR="#000000">Vice President, Finance &amp; Administration</FONT></DIV> <DIV STYLE="margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">and Chief Financial Officer</FONT></DIV> </TD> </TR>
   </TABLE> </DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Dated:&nbsp;&nbsp;&nbsp;&nbsp;May 24, 2002 </FONT></DIV> <P></P>
   <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">4 </FONT></DIV>
  
   </BODY></HTML>
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "d8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 15207}]
metadata_filer: {"company-data": {"conformed-name": "CONCEPTUS INC", "cik": "0000896778", "assigned-sic": "3841", "irs-number": "973170244", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-27596", "film-number": "02662332"}, "business-address": {"street1": "1021 HOWARD AVE", "city": "SAN CARLOS", "state": "CA", "zip": "94070", "phone": "4158027240"}, "mail-address": {"street1": "1021 HOWARD AVENUE", "city": "SAN CARLOS", "state": "CA", "zip": "94070"}}
text: Prepared by R.R. Donnelley Financial -- Form 8-K
  SECURITIES AND EXCHANGE COMMISSION
  WASHINGTON, D.C. 20549
  FORM 8-K
  Current Report
  Pursuant to Section 13 or 15(d) of The
  Securities Exchange Act of 1934
  Date of Report (Date of earliest event reported): May 23, 2002
  CONCEPTUS, INC.
  (Exact name of registrant as
  specified in charter)
  Delaware
  (State or other jurisdiction of
  incorporation or organization)
  000-27596
  (Commission file number)
  97-3170244
  (I.R.S. employer
  identification no.)
  1021 Howard Avenue
  San Carlos, CA 94070
  (Address of principal executive offices) (Zip code)
  Registrant's telephone number, including area code:    (650) 802-7240
  ITEM 5.    OTHER EVENTS.
  On May 23, 2002, Conceptus, Inc. issued a press release announcing that the Company's Premarket Approval (PMA) application for
  Essure
  has been accepted by U.S. Food and Drug Administration (FDA) as suitable for filing, and that the application will be reviewed during the July meeting of the FDA's Obstetrics and Gynecology Devices Panel. Text of the press release
  follows:
  SAN CARLOS, Calif. (May 23, 2002) – Conceptus, Inc. (NASDAQ NM: CPTS), developer
  of the non-incisional permanent birth control procedure
  Essure
  ™
  , has
  been advised by the U.S. Food and Drug Administration (FDA) that the Company's Premarket Approval (PMA) application for
  Essure
  has been accepted as suitable for filing, or deemed "fileable," and that the application will be
  reviewed during the July 22-23 meeting of the FDA's Obstetrics and Gynecology Devices Panel. In addition, the PMA application has been granted Expedited Review status. Based on the FDA Modernization Act of 1997, Expedited Review is granted for
  devices intended to provide a "more effective treatment or diagnosis of life-threatening or irreversibly debilitating human diseases or conditions." Accordingly, Expedited Review is to be granted "for devices: 1) representing
  breakthrough technologies; 2) for which no approved alternatives exist; 3) which offer significant advantages over existing approved alternatives; or, 4) the availability of which is in the best interest of patients."
  "We are grateful that the Agency has acted so swiftly in regards to our
  Essure
  PMA submission," commented Steven Bacich, chief executive
  officer. "In granting Expedited Review status, the FDA stated that they 'believe
  Essure
  may offer a significant advantage in female sterilization,' because, 'This device is delivered by a hysteroscopic procedure, without
  the need for an abdominal incision. In addition, in the majority of women, the placement procedure does not require general anesthesia.'"
  In commenting on U.S. commercialization, Steve Bowman, senior vice president of sales and marketing, said, "We intend to immediately commence certain aspects of our commercialization plan for Essure in the U.S., and to be ready
  to market shortly after receiving approval. In anticipation of potential FDA approval which, given the Expedited Review and the July Panel meeting, could come as early as the end of this year, we plan to accelerate our preparatory activities for
  U.S. commercialization so that we may bring this innovative method of permanent birth control to the women of the United States in the most expeditious manner possible."
  Cindy Domecus, senior vice president of clinical research and regulatory affairs, said, "According to the FDA's guidelines on Expedited Review, our application should receive priority review
  before other pending applications. Furthermore, the guidelines state that our application should be reviewed in the most efficient manner, be tracked as an Expedited Review, and be completed within the statutory time frames."
  The first module of the
  Essure
  PMA was filed last November, and the final PMA application was submitted to the FDA on April 19, 2002. The PMA
  submission included one-year data on 360 women with bilateral placement in the Pivotal trial. When combined with data from the Phase II trial, the PMA contained data on almost 900 women-years of reliance on the device. By the time of the panel
  review, data on 400 women with bilateral placement and one-year follow-up will have been submitted. To date, there have been no reported pregnancies in woman relying on Essure in either the Phase II or Pivotal trials, which supports a projected
  one-year effectiveness rate of 99.8%. The Company cautions that no method of birth control is 100% effective and that pregnancies are expected to occur.
  2
  PERMANENT BIRTH CONTROL
  According to the United States Centers for Disease Control and Prevention, surgical tubal ligation continues to be the most prevalent form of birth control in the U.S., with 41 percent of women using
  contraceptives age 35-39 and 50 percent of women using contraceptives age 40-44 having had a surgical tubal sterilization. An estimated 700,000 surgical tubal ligations are performed each year in the United States, despite the fact that it is
  invasive and costly. About 93 percent of the laparoscopic procedures in the U.S. are performed in a hospital or surgi-center under general anesthesia, requiring between four and five hours of hospital recovery time and four to six days before
  returning to regular activities.
  Development of a non-incisional method of tubal ligation has been an elusive goal for researchers since
  the 1970's.
  Essure
  is currently an investigational device for non-incisional permanent birth control.
  ABOUT
  CONCEPTUS
  Conceptus, Inc. is developing
  Essure
  , an innovative medical procedure, designed to provide a non-incisional
  alternative to tubal ligation, the leading form of birth control worldwide. The availability of
  Essure
  in the U.S. is projected for 2003 and is expected to open up a market currently occupied by surgical tubal ligation and vasectomy, which
  combined account for more than 1 million procedures in the United States.
  The
  Essure
  procedure is based on a unique and
  proprietary implant and catheter delivery system for minimally invasive transcervical tubal access.
  Except for the historical
  information contained herein, the matters discussed in this press release are forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. The receipt and timing of regulatory approvals, results of product
  development programs, and clinical efficacy of and market demand for our product, among other matters discussed in this release, may differ significantly from the discussion of such matters in the forward-looking statements. Such differences may be
  based upon factors such as strategic planning decisions by management, re-allocation of internal resources, performance of independent distributors, delays by regulatory authorities, scientific advances by third parties, introduction of competitive
  products, as well as those factors set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2001 and other filings with the Securities and Exchange Commission.
  #            #            #
  3
  SIGNATURES
  Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
  authorized.
  CONCEPTUS, INC.
  (Registrant)
  By:
  /s/    Glen K. Furuta
  Glen K. Furuta
  Vice President, Finance & Administration
  and Chief Financial Officer
  Dated:    May 24, 2002
  4